vs
Emergent BioSolutions Inc.（EBS）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Emergent BioSolutions Inc.的1.5倍（$217.4M vs $148.7M），Rapid7, Inc.净利率更高（1.4% vs -36.7%，领先38.2%），Rapid7, Inc.同比增速更快（0.5% vs -23.6%），Emergent BioSolutions Inc.自由现金流更多（$73.8M vs $36.4M），过去两年Rapid7, Inc.的营收复合增速更高（3.0% vs -29.6%）
Emergent BioSolutions是一家总部位于美国马里兰州盖瑟斯堡的跨国专业生物制药企业，公司专注于开发针对传染病及阿片类药物过量的疫苗与抗体疗法，同时还为生物防御领域提供相关医疗设备支持。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
EBS vs RPD — 直观对比
营收规模更大
RPD
是对方的1.5倍
$148.7M
营收增速更快
RPD
高出24.1%
-23.6%
净利率更高
RPD
高出38.2%
-36.7%
自由现金流更多
EBS
多$37.4M
$36.4M
两年增速更快
RPD
近两年复合增速
-29.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.7M | $217.4M |
| 净利润 | $-54.6M | $3.1M |
| 毛利率 | 42.9% | 68.9% |
| 营业利润率 | -18.8% | 1.0% |
| 净利率 | -36.7% | 1.4% |
| 营收同比 | -23.6% | 0.5% |
| 净利润同比 | -74.4% | 44.1% |
| 每股收益（稀释后） | $-0.95 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EBSRPD
| Q4 25 | $148.7M | $217.4M | ||
| Q3 25 | $231.1M | $218.0M | ||
| Q2 25 | $140.9M | $214.2M | ||
| Q1 25 | $222.2M | $210.3M | ||
| Q4 24 | $194.7M | $216.3M | ||
| Q3 24 | $293.8M | $214.7M | ||
| Q2 24 | $254.7M | $208.0M | ||
| Q1 24 | $300.4M | $205.1M |
净利润EBSRPD
| Q4 25 | $-54.6M | $3.1M | ||
| Q3 25 | $51.2M | $9.8M | ||
| Q2 25 | $-12.0M | $8.3M | ||
| Q1 25 | $68.0M | $2.1M | ||
| Q4 24 | $-31.3M | $2.2M | ||
| Q3 24 | $114.8M | $15.4M | ||
| Q2 24 | $-283.1M | $6.5M | ||
| Q1 24 | $9.0M | $1.4M |
毛利率EBSRPD
| Q4 25 | 42.9% | 68.9% | ||
| Q3 25 | 62.8% | 70.2% | ||
| Q2 25 | 52.5% | 70.6% | ||
| Q1 25 | 60.2% | 71.7% | ||
| Q4 24 | 39.4% | 69.5% | ||
| Q3 24 | 54.9% | 70.6% | ||
| Q2 24 | -18.8% | 70.7% | ||
| Q1 24 | 49.2% | 70.3% |
营业利润率EBSRPD
| Q4 25 | -18.8% | 1.0% | ||
| Q3 25 | 33.1% | 2.7% | ||
| Q2 25 | 1.1% | 1.6% | ||
| Q1 25 | 22.5% | -0.0% | ||
| Q4 24 | -4.9% | 3.4% | ||
| Q3 24 | 22.0% | 6.0% | ||
| Q2 24 | -79.9% | 2.5% | ||
| Q1 24 | 13.2% | 4.7% |
净利率EBSRPD
| Q4 25 | -36.7% | 1.4% | ||
| Q3 25 | 22.2% | 4.5% | ||
| Q2 25 | -8.5% | 3.9% | ||
| Q1 25 | 30.6% | 1.0% | ||
| Q4 24 | -16.1% | 1.0% | ||
| Q3 24 | 39.1% | 7.2% | ||
| Q2 24 | -111.2% | 3.1% | ||
| Q1 24 | 3.0% | 0.7% |
每股收益（稀释后）EBSRPD
| Q4 25 | $-0.95 | $0.05 | ||
| Q3 25 | $0.91 | $0.15 | ||
| Q2 25 | $-0.22 | $0.13 | ||
| Q1 25 | $1.19 | $0.03 | ||
| Q4 24 | $-0.45 | $0.08 | ||
| Q3 24 | $2.06 | $0.21 | ||
| Q2 24 | $-5.38 | $0.09 | ||
| Q1 24 | $0.17 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $205.4M | $474.7M |
| 总债务越低越好 | $589.7M | — |
| 股东权益账面价值 | $522.6M | $154.7M |
| 总资产 | $1.3B | $1.7B |
| 负债/权益比越低杠杆越低 | 1.13× | — |
8季度趋势，按日历期对齐
现金及短期投资EBSRPD
| Q4 25 | $205.4M | $474.7M | ||
| Q3 25 | $245.5M | $407.1M | ||
| Q2 25 | $267.3M | $511.7M | ||
| Q1 25 | $149.1M | $493.5M | ||
| Q4 24 | $99.5M | $521.7M | ||
| Q3 24 | $149.9M | $443.7M | ||
| Q2 24 | $69.7M | $442.6M | ||
| Q1 24 | $78.5M | $411.7M |
总债务EBSRPD
| Q4 25 | $589.7M | — | ||
| Q3 25 | $693.1M | — | ||
| Q2 25 | $700.0M | — | ||
| Q1 25 | $700.0M | — | ||
| Q4 24 | $700.0M | — | ||
| Q3 24 | $700.8M | — | ||
| Q2 24 | $863.8M | — | ||
| Q1 24 | $909.2M | — |
股东权益EBSRPD
| Q4 25 | $522.6M | $154.7M | ||
| Q3 25 | $582.5M | $127.2M | ||
| Q2 25 | $536.2M | $90.4M | ||
| Q1 25 | $552.7M | $52.7M | ||
| Q4 24 | $482.8M | $17.7M | ||
| Q3 24 | $508.4M | $-5.1M | ||
| Q2 24 | $386.3M | $-52.6M | ||
| Q1 24 | $663.9M | $-86.4M |
总资产EBSRPD
| Q4 25 | $1.3B | $1.7B | ||
| Q3 25 | $1.5B | $1.7B | ||
| Q2 25 | $1.4B | $1.6B | ||
| Q1 25 | $1.4B | $1.6B | ||
| Q4 24 | $1.4B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.8B | $1.5B |
负债/权益比EBSRPD
| Q4 25 | 1.13× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | 1.27× | — | ||
| Q4 24 | 1.45× | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | 2.24× | — | ||
| Q1 24 | 1.37× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $77.7M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $73.8M | $36.4M |
| 自由现金流率自由现金流/营收 | 49.6% | 16.8% |
| 资本支出强度资本支出/营收 | 2.6% | 0.5% |
| 现金转化率经营现金流/净利润 | — | 12.01× |
| 过去12个月自由现金流最近4个季度 | $156.8M | $146.2M |
8季度趋势，按日历期对齐
经营现金流EBSRPD
| Q4 25 | $77.7M | $37.6M | ||
| Q3 25 | $-2.3M | $39.0M | ||
| Q2 25 | $106.4M | $47.5M | ||
| Q1 25 | $-11.2M | $29.8M | ||
| Q4 24 | $-79.9M | $63.8M | ||
| Q3 24 | $153.7M | $44.0M | ||
| Q2 24 | $47.5M | $32.9M | ||
| Q1 24 | $-62.6M | $31.1M |
自由现金流EBSRPD
| Q4 25 | $73.8M | $36.4M | ||
| Q3 25 | $-5.7M | $34.8M | ||
| Q2 25 | $103.5M | $46.6M | ||
| Q1 25 | $-14.8M | $28.4M | ||
| Q4 24 | $-81.6M | $62.6M | ||
| Q3 24 | $147.9M | $42.6M | ||
| Q2 24 | $42.9M | $32.6M | ||
| Q1 24 | $-73.4M | $30.4M |
自由现金流率EBSRPD
| Q4 25 | 49.6% | 16.8% | ||
| Q3 25 | -2.5% | 16.0% | ||
| Q2 25 | 73.5% | 21.8% | ||
| Q1 25 | -6.7% | 13.5% | ||
| Q4 24 | -41.9% | 28.9% | ||
| Q3 24 | 50.3% | 19.9% | ||
| Q2 24 | 16.8% | 15.7% | ||
| Q1 24 | -24.4% | 14.8% |
资本支出强度EBSRPD
| Q4 25 | 2.6% | 0.5% | ||
| Q3 25 | 1.5% | 1.9% | ||
| Q2 25 | 2.1% | 0.4% | ||
| Q1 25 | 1.6% | 0.6% | ||
| Q4 24 | 0.9% | 0.5% | ||
| Q3 24 | 2.0% | 0.6% | ||
| Q2 24 | 1.8% | 0.1% | ||
| Q1 24 | 3.6% | 0.3% |
现金转化率EBSRPD
| Q4 25 | — | 12.01× | ||
| Q3 25 | -0.04× | 3.97× | ||
| Q2 25 | — | 5.70× | ||
| Q1 25 | -0.16× | 14.14× | ||
| Q4 24 | — | 29.36× | ||
| Q3 24 | 1.34× | 2.85× | ||
| Q2 24 | — | 5.03× | ||
| Q1 24 | -6.96× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EBS
| Medical Countermeasures MCM Product | $99.2M | 67% |
| Commercial Products Segment | $38.4M | 26% |
| All Other Revenue | $11.1M | 7% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
